FairJourney Biologics Acquires South San Francisco Site to Enhance Antibody Discovery
Deal News | Mar 10, 2025 | GHO Capital Partners LLP
FairJourney Biologics S.A., a leader in antibody discovery and optimization, has announced the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. This acquisition is part of FairJourney's strategic growth plan and will enhance its capabilities in antibody discovery and engineering. By acquiring this site, previously known as Distributed Bio, FairJourney will gain not only facilities and assets but also proprietary technologies such as the SuperHuman, Cosmic, and Tungsten libraries, alongside the Yeast Display method. This move strengthens FairJourney's presence in North America's prominent biotechnology hub, providing localized expertise and support to customers there and paving the way for collaborations with major biotech and pharmaceutical firms.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- United States – The acquisition involves a site in South San Francisco, a key biotechnology hub in the US, expanding FairJourney's market presence.
- United Kingdom – GHO Capital Partners LLP, the private equity firm overseeing FairJourney, is based in London, UK.
- Portugal – FairJourney Biologics S.A., the acquiring company, is based in Portugal, indicating a geographical span in this transaction.
Industry
- Biotechnology – The biotechnology sector is central to the article as FairJourney Biologics enhances its capabilities in antibody discovery through biotechnology-focused assets and expertise.
- Healthcare – GHO Capital Partners LLP, the private equity firm involved, specializes in healthcare investments, demonstrating relevance to the healthcare industry.
- Private Equity – GHO Capital Partners LLP's involvement in the acquisition highlights the role of private equity in facilitating strategic growth in the healthcare and biotech sectors.
Financials
- – The article does not specify the financial terms of this acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| FairJourney Biologics S.A. | Target company | Company | A leading company in antibody discovery and optimization. |
| Charles River Laboratories International, Inc. | Selling company | Company | Previously owned the South San Francisco site, now acquired by FairJourney Biologics. |
| GHO Capital Partners LLP | Private Equity firm | Company | European specialist investor in global healthcare, owner of FairJourney Biologics. |
| António Parada | CEO, FairJourney Biologics | Person | Leader responsible for strategic decisions at FairJourney Biologics. |